Boron-based compounds
NTM Lung Disease (M. abscessus)
Key Facts
About AN2 Therapeutics
AN2 Therapeutics is focused on discovering and developing novel therapeutics derived from its boron chemistry platform, which enables the creation of selective inhibitors for challenging biological targets. The company has a pipeline of boron-based compounds in clinical and preclinical development for infectious diseases, including its lead candidate for Chagas disease. With experienced leadership from Anacor Pharmaceuticals and a commitment to global health, AN2 aims to deliver high-impact drugs to address critical unmet needs.
View full company profileAbout AN2 Therapeutics
AN2 Therapeutics is focused on discovering and developing novel therapeutics derived from its boron chemistry platform, which enables the creation of selective inhibitors for challenging biological targets. The company has a pipeline of boron-based compounds in clinical and preclinical development for infectious diseases, including its lead candidate for Chagas disease. With experienced leadership from Anacor Pharmaceuticals and a commitment to global health, AN2 aims to deliver high-impact drugs to address critical unmet needs.
View full company profileAbout AN2 Therapeutics
AN2 Therapeutics is focused on discovering and developing novel therapeutics derived from its boron chemistry platform, which enables the creation of selective inhibitors for challenging biological targets. The company has a pipeline of boron-based compounds in clinical and preclinical development for infectious diseases, including its lead candidate for Chagas disease. With experienced leadership from Anacor Pharmaceuticals and a commitment to global health, AN2 aims to deliver high-impact drugs to address critical unmet needs.
View full company profile